TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug …
[Read more...] about Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Press Release
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner with Industry Leader WuXi XDC For This Key IND-enabling Work Tampa, FL and London – December 23, 2025 – Akari …
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Access the Akari CEO Corner here BOSTON and LONDON – November 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing …
[Read more...] about Akari Therapeutics Announces Release of the Next CEO Corner Segment
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven …
Akari Therapeutics Presents Promising Immuno-OncologyData for its Novel Splicing-Targeted ADC Payload Driving ImmuneActivation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, …
